Patents by Inventor Michael Chastain
Michael Chastain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9990662Abstract: A computer-assisted inspection system provides computer architectures and software controlled algorithms to automatically provide vehicle inspections and repair recommendations including estimated repair time and cost of depression type damage such as dents. Features provided by a handheld wireless touchscreen based inspection device include flat car part picking, auto grading including seller grading, and automatic calculation of body and bumper dent repair parameters and directions.Type: GrantFiled: September 29, 2015Date of Patent: June 5, 2018Assignee: Manheim Investments, Inc.Inventors: William Henry Couch, Julie Elizabeth Warpool, Mark Humble, Marc Haegelin, Stephen Krise, Michael Chastain, Ronald St. Denis, Terry Mitchell
-
Publication number: 20160019616Abstract: A computer-assisted inspection system provides computer architectures and software controlled algorithms to automatically provide vehicle inspections and repair recommendations including estimated repair time and cost of depression type damage such as dents. Features provided by a handheld wireless touchscreen based inspection device include flat car part picking, auto grading including seller grading, and automatic calculation of body and bumper dent repair parameters and directions.Type: ApplicationFiled: September 29, 2015Publication date: January 21, 2016Inventors: William Henry COUCH, Julie Elizabeth WARPOOL, Mark HUMBLE, Marc HAEGELIN, Stephen KRISE, Michael CHASTAIN, Ronald ST. DENIS, Terry MITCHELL
-
Patent number: 9189960Abstract: A computer-assisted inspection system provides computer architectures and software controlled algorithms to automatically provide vehicle inspections and repair recommendations including estimated repair time and cost of depression type damage such as dents. Features provided by a handheld wireless touchscreen based inspection device include flat car part picking, auto grading including seller grading, and automatic calculation of body and bumper dent repair parameters and directions.Type: GrantFiled: April 30, 2012Date of Patent: November 17, 2015Assignee: MANHEIM INVESTMENTS, INC.Inventors: William Henry Couch, Julie Elizabeth Warpool, Mark Humble, Marc Haegelin, Stephen Krise, Michael Chastain, Ronald St. Denis, Terry Mitchell
-
Publication number: 20150079080Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: September 22, 2014Publication date: March 19, 2015Inventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Nelly Kuklin, Michael Chastain, David G. Brooks, Lee J. Helman
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20150078996Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: September 19, 2014Publication date: March 19, 2015Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Publication number: 20130273031Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: February 26, 2013Publication date: October 17, 2013Inventors: LILIANE GOETSCH, NATHALIE CORVAIA, OLIVIER LEGER, NELLY KUKLIN, MICHAEL CHASTAIN, DAVID G. BROOKS, LEE J. HELMAN
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20130084243Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: November 29, 2012Publication date: April 4, 2013Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
Patent number: 8344112Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGF-1R.Type: GrantFiled: July 25, 2008Date of Patent: January 1, 2013Assignee: Merck Sharp & Dohme LimitedInventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Publication number: 20120297337Abstract: A computer-assisted inspection system provides computer architectures and software controlled algorithms to automatically provide vehicle inspections and repair recommendations including estimated repair time and cost of depression type damage such as dents. Features provided by a handheld wireless touchscreen based inspection device include flat car part picking, auto grading including seller grading, and automatic calculation of body and bumper dent repair parameters and directions.Type: ApplicationFiled: April 30, 2012Publication date: November 22, 2012Applicant: MANHEIM INVESTMENTS, INC.Inventors: Ronald St. Denis, Terry Mitchell, Mark Humble, Marc Haegelin, William Henry Couch, Julie Elizabeth Warpool, Stephen Krise, Michael Chastain
-
Publication number: 20120058112Abstract: The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.Type: ApplicationFiled: April 6, 2010Publication date: March 8, 2012Inventors: Sriram Sathyanarayanan, Shailaja Kashibhatla, Christopher Winter, Michael Chastain
-
Publication number: 20100280987Abstract: Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of RAS pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating RAS pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated RAS signaling pathway; determining whether an agent modulates the RAS signaling pathway in sample; predicting response of a subject to an agent that modulates the RAS signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of cancer therapies designed to regulate RAS pathway signaling.Type: ApplicationFiled: April 16, 2010Publication date: November 4, 2010Inventors: Andrey Loboda, Michael Nebozhyn, Theresa Zhang, James W. Watters, Pearl S. Huang, Michael Chastain, Richard A. Klinghoffer
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20100215573Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: July 25, 2008Publication date: August 26, 2010Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Publication number: 20080254059Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided.Type: ApplicationFiled: February 7, 2006Publication date: October 16, 2008Inventors: Andrew J. Bett, Danilo R. Casimiro, John W. Shiver, Emilio A. Emini, Michael Chastain, David C. Kaslow
-
Publication number: 20080193445Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: May 8, 2007Publication date: August 14, 2008Inventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Nelly Kuklin, Michael Chastain
-
Publication number: 20050106123Abstract: An efficient means of inducing an immune response against human immunodeficiency virus (“HIV”) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol wherein recombinant adenoviral and poxvirus vectors comprising exogenous genetic material encoding a common HIV antigen are administered in that order. Vaccines administered into living vertebrate tissue in accordance with the disclosed regimes, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 antigen (e.g., Gag), inducing a cellular immune response which specifically recognizes HIV-1. It is believed that the disclosed prime/boost regime will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.Type: ApplicationFiled: March 12, 2003Publication date: May 19, 2005Inventors: Emilio Emini, John Shiver, Michael Chastain, Danilo Casimiro, Tong-Ming Fu, Xiaoping Liang
-
Publication number: 20040191222Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g, fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 34, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for the delivery and expression of exogenous genes are provided.Type: ApplicationFiled: August 21, 2003Publication date: September 30, 2004Inventors: Emilio A. Emini, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, David C. Kaslow, Michael Chastain
-
Publication number: 20040185555Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g, fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 24, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for the delivery and expression of exogenous genes are provided.Type: ApplicationFiled: August 21, 2003Publication date: September 23, 2004Inventors: Emilio A. Emini, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, Michael Chastain, David C. Kaslow, Manal Morsy
-
Patent number: 6787351Abstract: An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.Type: GrantFiled: March 27, 2001Date of Patent: September 7, 2004Assignee: Merck & Co., Inc.Inventors: Ling Chen, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, Michael J. Caulfield, Michael A. Chastain, Emilio A. Emini
-
Publication number: 20040106194Abstract: Various methods for propagating and rescuing multiple serotypes of replication-defective adenovirus in a single adenoviral E1-complementing cell line are disclosed. Typically, replication-defective adenovirus vectors propagate only in cell lines which express E1 proteins of the same serotype or subgroup as the vector. The disclosed methods offer the ability to propagate vectors derived from multiple adenoviral serotypes in a single production cell line which expresses E1 proteins from a single serotype. Propagation in this manner is accomplished by providing all or a portion of an E4 region in cis within the genome of the replication-defective adenovirus. The added E4 region or portion thereof is cloned from a virus of the same or highly similar serotype as that of the E1 gene product(s) of the complementing cell line. Interaction between the expressed E1 of the cell line and the heterologous E4 of the replication-defective adenoviral vectors enables their propagation and rescue.Type: ApplicationFiled: August 21, 2003Publication date: June 3, 2004Inventors: Andrew J. Bett, Michael Chastain, Volker Sandig, Emilio A. Emini, John W. Shiver, Danilo R. Casimiro, David C. Kaslow, Manal Morsy
-
Patent number: D1004842Type: GrantFiled: February 18, 2021Date of Patent: November 14, 2023Assignee: Parlor Studio LLCInventors: Jeff Michael Chastain, Juergen Nott